AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. (Q36338069)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

clear cell carcinoma

1 reference

based on heuristic

inferred from title

Andrzej Deptała

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Cezary Szczylik

2

object named as

Cezary Szczylik

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Brian Rini

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Nizar M Tannir

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Piotr Koralewski

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Piotr Tomczak

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Luc Y Dirix

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Mayer Fishman

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Wojciech Rogowski

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Karolyn Kracht

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Yu-Nien Sun

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Michael B Bass

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Markus Puhlmann

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Bernard Escudier

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

0 references

publication date

12 June 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

118

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

6152-6161

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

The role of vascular cell adhesion molecule-1 in tumor immune evasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

30 September 2017

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

22 September 2018

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

22 September 2018

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

22 September 2018

Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666535

22 September 2018

Renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27632

21 January 2018

Circulating biomarkers of bevacizumab activity in patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22692704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22692704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

1 reference

https://pubmed.ncbi.nlm.nih.gov/22692704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22692704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22692704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.27632

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692704%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36338069&oldid=1773661663"